However, in triple-negative breast cancer, the ORRs of pembrolizumab were similar in PD-L1-positive (CPS ≥ 1) and PD-L1-negative (CPS < 1) populations [68]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.